PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

GSK’s Arexvy authorised by MHRA

Therapy is the first respiratory syncytial virus vaccine specifically developed for older adults.

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Arexvy. The therapy is for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by a respiratory syncytial virus (RSV) among adults of 60 years and above.

It is the first time an RSV vaccine, specifically for older adults, has been authorised for use across Great Britain by the MHRA.

The authorisation follows data from the critical AReSVi-006 phase 3 vaccine efficacy study, published in the New England Journal of Medicine. During the trial, there was high overall vaccine efficacy against RSV-LRTD, including in participants with a variety of underlying medical conditions.

Furthermore, the vaccine was generally well tolerated, while the most prevalent adverse events were injection site pain, myalgia, fatigue, arthralgia and headaches. The events were generally mild-to-moderate.

Neale Belson, senior vice president, and general manager UK at GSK, elaborated: “We are very excited by today’s announcement. Our ambition is to help protect adults 60 years of age and older in the UK who are at risk from RSV disease, including those with underlying medical conditions, who drive the majority of RSV hospitalisations.”

He added: “This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time, reinforcing GSK’s long history of vaccine innovation.”

The MHRA’s decision arrives after the European Commission’s authorisation of Arexvy this year. GSK’s marketing authorisation application in the EU was reviewed under the ‘accelerated assessment mechanism’ because prevention of RSV illness in the older adult population is still considered a significant public health interest.

RSV remains a common and contagious respiratory virus that leads to an estimated 175,000 GP visits, 14,000 hospitalisations and 8,000 deaths each year in adults aged 60 years and over in the UK.

Arexvy was the world’s first RSV vaccine for older adults to be approved by the US Food and Drug Administration, while regulatory reviews are currently unfolding in Japan along with several other countries.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026